Glucose management impact of "asken medical system" in patients with type 2 diabetes.

Glucose management impact of "asken medical system" in patients with type 2 diabetes. - asknDTx

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs052220099

Enrollment

Registered

2022-09-27

Start date

2022-11-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Medical nutrition therapy with "asken medical system"

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Type 2 diabetes 2) Diabetic nephropathy stage 1 or 2 3) Aged 20 y.o. or older 4) HbA1c >= 7.0% 5) Mobile device user 6) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Using application assessing dietary intake 2) Pregnant or suspected to be pregnant 3) Breastfeeding 4) Less than 84 days after diagnosed with diabetes 5) Continuous administration of steroids 6) eGFR < 45ml/min/1.73cm2 7) Chronic pancreatitis or pancreatic cancer 8) Liver cirrhosis 9) Decompensated heart failure 10) Drug or alcohol dependence 11) Unstable mental disease 12) Malignant tumor 13) Comorbidity affecting primary outcome 14) Inappropriate for inclusion in the study

Design outcomes

Primary

Measure	Time frame
Cange of time in range (%) at 4 weeks	—

Secondary

Measure	Time frame
1)Change of body weight 2)Change of clinical data (HbA1c, glycated albumin, LDL, HDL, urine protein, urine urea nitrogen) 3)Time above range (>=180mg/dl), Time below range (<70mg/dl), mean glucose 4)Dietary intake at 4th week (Intervention group only)	—

Contacts

Public ContactAki Kondo

Graduate School of Medicine Kyoto University

akondo@kuhp.kyoto-u.ac.jp+81-75-751-3560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026